These clinical performance measures are designed for individual quality improvement. Some of the measures may also be appropriate for accountability if appropriate sample sizes and implementation rules are achieved.
Intended Audience and Patient Population:
Any hematologist caring for patients age 18 years and older with myelodysplastic syndrome, acute leukemias, multiple myeloma, or chronic lymphocytic leukemia.
- Overview of Measure Development Process
- Myelodysplastic Syndrome and Acute Leukemias
CMS Measure #67 (Hematology Measure #1) - Baseline cytogenetic testing performed on bone marrow
- Myelodysplastic Syndrome
CMS Measure #68 (Hematology Measure #2) - Documentation of baseline iron stores in patients receiving erythropoietin therapy
- Multiple Myeloma
CMS Measure #69 (Hematology Measure #3) - Treatment with bisphosphonates
- Chronic Lymphocytic Leukemia
CMS Measure #70 (Hematology Measure #4) - Baseline flow cytometry
The following Health Information Technology Measure may also be of use to hematologists:
- Adoption/Use of Health Information Technology
CMS Measure #124 - Electronic health records
back to top
